Hal-abuurka Daawaynta Hidde-sidaha Waxay Rajo Cusub u tahay Bukaannada Sickle Cell iyo Thalassaemia

Hal-abuurka Daawaynta Hidde-sidaha Waxay Rajo Cusub u tahay Bukaannada Sickle Cell iyo Thalassaemia

Horumarka aasaasiga ah ee bukaanada la ildaran cudurka sickle cell (SCD) iyo thalassaemia, daawaynta hidda-wadaha cusub ayaa muujinaya guul cajiib ah. Daawayntan, oo adeegsata tignoolajiyada tafatirka hidda-wadaha CRISPR/Cas9 ee horumarsan, waxay muujisay 100% heerka daawaynta ee tijaabooyinka bukaan-socodka, taasoo rajo cusub siinaysa kuwa la dagaallamaya cudurradan daran ee dhiigga.

Daawaynta, oo lagu sameeyay habka gaarka ah ee ModiHSC®, waxa lagu bartilmaameedsadaa xididdada hidde-sideyaasha SCD iyo thalassaemia. Adigoo si sax ah u tafatiraaya kor u qaadaya BCL11A ee stem hematopoietic autologous iyo unugyada hore, daawaynta waxay awood u siinaysaa jidhka inuu soo saaro heerar sare oo haemoglobin uurjiif ah (HbF). Heerarka sare ee HbF ayaa la muujiyay si ay uga hortagaan waxyeelada waxyeelada leh ee hemoglobin sickle (HbS) waxayna yareeyaan calaamadaha SCD iyo thalassaemia labadaba, oo ay ku jiraan ka hortagga dhibaatooyinka vaso-occlusive iyo yaraynta dhiig-yaraanta hemolytic.

BOOCUS, oo ah cudud hormuud u ah daawaynta hidda-sidaha, iyada oo kaashanaysa Isbitaalka Lu Daopei, ayaa gacan ka geysatay keenista daaweyntan cusub ee bukaannada. 

Guusha daawaynta ayaa ah mid aan la soo koobi karin, iyadoo ilaa hadda la daweeyay 15 bukaan, kuwaas oo dhammaantood helay cafis dhammaystiran iyo horumar la taaban karo oo xagga tayada nolosha ah. Heerkan 100% ee daawadu waa guul muhiim ah oo laga gaaray dagaalka lagula jiro SCD iyo thalassaemia.

Daawaynta ayaa heshay aqoonsi caalami ah, iyadoo khubarada adduunka oo dhan ay ku ammaaneen inay tahay horumar laga gaaray daawaynta cilladaha dhiigga hidde-sidaha. Waxay u taagan tahay ma aha oo kaliya waxtarkeeda laakiin sidoo kale waxtarkeeda kharashka. Si ka duwan daaweynta hidde-sideyaasha kale, kuwaas oo noqon kara mid aad qaali u ah, daawayntani waxay bixisa qaab qiimeed oo la heli karo, taas oo ka dhigaysa ikhtiyaar macquul ah oo loogu talagalay bukaanno kala duwan.

Hal kiis oo khasab ah, bukaan 12 jir ah oo qaba qalalaasaha vaso-occlusive oo soo noqnoqda iyo dhiig-yaraan ba'an oo dhiig-yaraan ah ayaa la kulmay joojinta dhammaystiran ee calaamadaha ka dib daawaynta hidda-wadaha. Kiiskan, iyo kuwa kale, ayaa iftiiminaya kartida wax-ka-beddelka ee daawaynta ee SCD iyo bukaannada thalassaemia ee adduunka oo dhan.

Maaddaama BOOCUS ay sii waddo ballaarinta helitaanka daawayntan, oo ay ku jiraan tijaabooyinka caafimaad ee soo socda ee Shiinaha, mustaqbalku wuxuu u muuqdaa rajo kuwa ay saameeyeen cudurradan adag. Iyada oo taageero laga helayo Isbitaalka Lu Daopei, daawayntan ayaa loo dejiyay inay dib u qeexdo heerka daryeelka SCD iyo thalassaemia, iyadoo siinaya heshiis cusub oo nolosha bukaanno aan tiro lahayn.

Haddii adiga ama qof aad jeceshahay uu saameeyo cudurka sickle cell ama thalassaemia oo aad xiisaynayso inaad sahamiso daawayntan cusub, waxaanu kugu martiqaadaynaa inaad nala soo xidhiidho. Kooxdayadu waxay diyaar u tahay inay ku siiso taageerada iyo macluumaadka aad u baahan tahay si aad u gaadho go'aamo xog ogaal ah oo ku saabsan safarkaaga daryeelka caafimaadka.